SUGI HOLDINGS CO.LTD.

Company Overview

SUGI Holdings operates Japanese drugstores and dispensing pharmacies, concentrated in the Kanto, Chubu and Kansai regions but extending nationwide. It ended February 2026 with 2,321 locations and ¥1.010 trillion of revenue; the network reached 2,360 locations by August. Retail customers buy medicines, cosmetics, food and household goods, while patients and health insurers fund prescription dispensing. The investment outcome depends less on headline sales growth than on whether dispensing growth, purchasing scale and store density can offset wage inflation, reimbursement pressure and the capital consumed by acquisitions. The current price compensates for tax-related earnings normalization, but offers only modest protection if acquisition returns disappoint.

How the Company Makes Money

Fiscal 2026 sales comprised ¥307.3 billion of dispensing, ¥685.2 billion of merchandise and ¥17.8 billion of other revenue. Using disclosed purchases as a rough cost proxy, dispensing generated a mid-30% product spread versus a high-20% spread for merchandise. Dispensing was about 30% of revenue but roughly one-third of gross profit, before pharmacist wages and store overhead. It also brings recurring prescription traffic that can support retail purchases at attached drugstores.

Customers choose SUGI primarily for proximity, one-stop convenience and pharmacy capability rather than exclusive products. Local store density, relationships with medical institutions, about 6,600 pharmacists and a large app and loyalty base improve retention and allow targeted promotions. Procurement scale and supplier credit also matter: the business can sell inventory before paying suppliers, reducing working capital. These advantages are real but replicable. Competitors have comparable capital and locations, merchandise is largely identical, and regulated drug prices prevent conventional pricing power.

Fiscal 2026 gross margin rose from 31.3% to 31.8%, helped by procurement initiatives and a higher dispensing mix. SG&A simultaneously increased from 26.5% to 27.0% of sales as personnel, rent and payment fees rose, leaving operating margin essentially unchanged at 4.8%. That is a mid-ranking result: recent operating margins were approximately 7.6% at MatsukiyoCocokara, 5.6% at Sundrug, 4.8% at Create SD and 3.9% at Cosmos Pharmaceutical. SUGI has an efficient business, not an exceptional pricing moat.

Growth has historically created value: reported ROIC was 17.8% in fiscal 2026. However, the latest 15.1% revenue increase included acquisitions, 110 openings and 72 acquired pharmacies; existing-store sales grew a more representative 4.6%. The next year’s plan calls for 130 openings and approximately ¥25.7 billion of opening and refurbishment investment. Returns on the existing network are attractive, but returns on the larger acquisition-led expansion remain unproven.

Why the Stock Fell

On a split-adjusted basis, the shares fell from a January 20, 2026 close of ¥1,969 to ¥1,235.5 on September 18, a 37% decline. The first clear disappointment came on April 9: management forecast fiscal 2027 operating profit growth of 11.2%, but the anticipated 27.1% decline in net income and the pace of profit growth were viewed as insufficient relative to the prior valuation. The planned consolidation of Seki Yakuhin also introduced another acquisition whose final cost and returns were not yet quantified.

The sharper break followed the July 9 first-quarter release and equity financing. Revenue rose 10.1% and operating profit 10.9%, but ordinary profit increased only 1.9% because equity-method losses and interest costs absorbed much of the operating improvement. Operating-profit progress against full-year guidance was 22.6%, slightly below linear first-quarter pacing. At the same time, SUGI issued 5.082 million pre-split shares to GIC at ¥3,195, raising ¥16.2 billion and permanently diluting existing shareholders by 2.67%. The adjusted share price fell 11.1% between July 8 and July 10. Subsequent operating evidence was not disastrous: August existing-store sales rose 4.3%, including 9.7% dispensing growth, but the market continued to discount acquisition and reinvestment risk.

What the Market Is Assuming

The supplied February 2026 snapshot shows a ¥447.184 billion market capitalization, ¥290.474 billion book value, 1.54 times book, and ¥71.761 billion of owner earnings, equivalent to a 16.05% yield and 6.23-year payback. That cash yield is not sustainable as stated. Operating cash flow benefited from a ¥31.7 billion increase in trade payables, partly caused by year-end bank holidays, while reported net income included an unusually low tax charge following recognition of deferred tax assets.

The supplied market capitalization also predates the completed GIC issuance. After the issue and September stock split, estimated shares excluding treasury stock are approximately 372.1 million rather than the 361.9 million implicit in the supplied market capitalization. At ¥1,235.5, updated equity value is therefore about ¥459.7 billion. Conditional reverse valuation: a 9% required equity return with no growth requires roughly ¥41.4 billion of sustainable annual distributable earnings; a 10% return requires ¥46.0 billion. Against a normalized estimate near ¥39.5 billion, the price implies roughly 1% perpetual growth at a 9.5% required return. It does not require management’s full ¥1.6 trillion revenue and 5.5% margin targets, but it does require stable margins and disciplined reinvestment.

Temporary or Structural?

Verdict: mixed, with the recent earnings optics predominantly TIME and the capital-allocation change potentially ESSENCE. The forecast net-income decline is mostly temporary comparison noise. Fiscal 2026 profit before tax was ¥45.2 billion, yet taxes were only ¥0.2 billion after the I&H merger allowed additional deferred tax assets to be recognized. First-quarter fiscal 2027 net income consequently fell 67.5% when the tax rate normalized, while revenue and operating profit still grew about 10%. That does not demonstrate a deterioration in the stores’ underlying earning power.

The permanent risks are dilution and lower returns on future capital. The GIC issue reduced every existing shareholder’s claim by 2.67%, while its proceeds are earmarked for stores, DX and further M&A rather than immediate per-share accretion. Goodwill already stood at ¥43.1 billion, SUGI paid ¥22.5 billion for its initial 49% interest in Seki, and interest expense has risen. I&H, Seki and future targets must produce purchasing, staffing or revenue synergies large enough to exceed their financing and integration costs. Otherwise, group revenue can recover or grow while per-share cash economics deteriorate.

Industry cost pressure also has a structural component. Pharmacist scarcity, general wage inflation and periodic reductions in drug prices and dispensing remuneration cannot simply reverse with the cycle. SUGI has so far offset them through dispensing volume, procurement and productivity: first-quarter operating margin improved slightly to 4.5%, and August dispensing sales remained strong. The strongest contrary evidence is that full-year operating margin has not expanded despite better gross mix, while MatsukiyoCocokara earns materially higher margins. SUGI’s 5.5% target is achievable within the industry, but its own results have not yet established the route.

Survival is not the issue. Fiscal 2026 equity was ¥290.5 billion, the equity ratio was 47.3%, and the GIC transaction added fresh capital. Exact net cash remains unavailable in the supplied snapshot, and the final Seki consideration and post-consolidation balance sheet were not quantified in the latest materials reviewed. That uncertainty affects acquisition returns, not near-term solvency.

Is the Market Wrong? By How Much?

The asset case is weak: supplied NCAV is negative ¥12.924 billion and no defensible liquidation value is available. Valuation therefore rests on distributable going-concern earnings. The following bridge normalizes fiscal 2026 and then rolls forward using fiscal 2027 operating guidance.

Maintenance capital is estimated below total store and system investment because expansion capital must be retained to produce growth. No stock-compensation expense is added back; completed share issuance and treasury-share compensation are reflected through the approximately 372.1 million diluted share count. The valuation uses equity cash flow, so no separate cash or debt adjustment is added.

The evidence supports only modest mispricing in the base case. The stock appears cheap if the supplied 16.05% owner-earnings yield is accepted without adjustment, but normalized cash earnings suggest a much less dramatic discount. The price adequately recognizes the temporary tax reversal and permanent dilution; it may understate the value of continued dispensing growth, but base-case upside of about 8% is not a large margin of safety. The assumption most capable of overturning that judgment is whether acquisition-led growth can lift per-share cash flow without recurring equity issuance or declining returns on capital.

Key Facts, Estimates, and Judgments